纈沙坦聯(lián)合氨氯地平治療老年原發(fā)高血壓合并糖尿病療效觀察

徐炳君

[摘要] 目的 觀察纈沙坦聯(lián)合氨氯地平治療老年原發(fā)高血壓合并糖尿病療效。方法 以該院2018年1月—2019年7月間收治的老年原發(fā)高血壓合并糖尿病患者中選取104例作為實驗案例均分兩組，參照組52例患者接受氨氯地平藥物治療，研討組52例患者接受氨氯地平聯(lián)合纈沙坦治療，觀察疾病療效。 結(jié)果 治療后研討組2項血壓及2項血糖指標(biāo)相對于參照組有更明顯的下降，同時研討組治療總體有效性90.38%，參照組治療總體有效性63.46%，研討組療效優(yōu)于參照組，組間比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 纈沙坦聯(lián)合氨氯地平治療老年原發(fā)高血壓合并糖尿病療效甚佳，能夠改善患者血壓及血糖水平。

[關(guān)鍵詞] 纈沙坦;氨氯地平;老年原發(fā)高血壓;糖尿病;療效觀察

[中圖分類號] R4 ? ? ? ? ?[文獻(xiàn)標(biāo)識碼] A ? ? ? ? ?[文章編號] 1672-4062（2020）05（b）-0014-03

Observation on the Efficacy of Valsartan Combined with Amlodipine in the Treatment of Elderly Hypertension with Diabetes

XU Bing-jun

Department of Emergency Medicine， Junan County Traditional Chinese Medicine Hospital， Junan， Shandong Province， 276600 China

[Abstract] Objective To observe the efficacy of valsartan combined with amlodipine in the treatment of senile essential hypertension with diabetes. Methods A total of 104 elderly patients with primary hypertension and diabetes treated in the hospital from January 2018 to July 2019 were selected as experimental cases and divided into 2 groups. 52 patients in the reference group received amlodipine drug treatment， and the study group of 52 patients received amlodipine combined with valsartan to observe the effect of the disease. Results After treatment， the two blood pressure and two blood glucose indexes of the study group decreased more significantly than the reference group. At the same time， the overall effectiveness of the treatment group was 90.38%， and the overall effectiveness of the reference group was 63.46%. The treatment group was better than the reference group. There were statistically significant differences between groups（P<0.05）. Conclusion Valsartan combined with amlodipine is effective in treating elderly patients with hypertension and diabetes. It can improve patients' blood pressure and blood glucose levels.

[Key words] Valsartan; Amlodipine; Elderly hypertension; Diabetes; Efficacy observation

高血壓是臨床一種典型的慢性心血管疾病，是引發(fā)患者心臟病、腎衰竭、中風(fēng)、血管瘤等諸多疾病的誘因[1]。老年群體是高血壓的高發(fā)人群，發(fā)生率達(dá)到49.7%以上，主要是由于老年人身體免疫力、抵抗力下降，往往易合并糖尿病[2]。對于老年原發(fā)高血壓合并糖尿病的治療關(guān)鍵點在于胰島素抵抗，這是因胰島素與患者預(yù)后恢復(fù)關(guān)系密切[3]。臨床治療常采取聯(lián)合用藥方式，并遵循提高藥效、減輕藥物副反應(yīng)、改善代謝綜合征、保護(hù)靶器官為原則[4]。該文圍繞該院于2018年1月—2019年7月收治的104例老年原發(fā)高血壓合并糖尿病患者分組采用氨氯地平與其聯(lián)合纈沙坦治療，觀察其治療效果，現(xiàn)報道如下。

1 ?資料與方法

1.1 ?一般資料

以該院收治的老年原發(fā)高血壓合并糖尿病患者中選取104例作為實驗案例均分兩組，參照組52例患者接受氨氯地平藥物治療，研討組52例患者接受氨氯地平聯(lián)合纈沙坦治療，觀察疾病療效。納入標(biāo)準(zhǔn)：符合中華醫(yī)學(xué)會制定的原發(fā)高血壓合并糖尿病相關(guān)診斷標(biāo)準(zhǔn)，患者年齡于60歲以上，對于該研究內(nèi)容知曉，患者及其親屬自愿簽署知情同意書。排除標(biāo)準(zhǔn)：合并肝、腎臟器功能衰竭或障礙等患者，治療依從性差，難以配合治療開展的患者。